Investigators sought to determine whether patients with cutaneous lupus erythematosus have a similar frequency of antimalarial adverse cutaneous drug eruptions to patients with dermatomyositis.
One-third of patients with refractory anti-HMGCR antibodies had improved strength or other evidence of improved disease activity after rituximab treatment.
The signs and symptoms associated with disease activity in juvenile dermatomyositis could be used to stratify patients and adapt treatment plans.
Statin exposure was significantly associated with histologically confirmed idiopathic inflammatory myositis.
Low nailfold capillary density is associated with impaired pulmonary function tests and more frequent high-resolution computed tomography abnormalities in patients with juvenile dermatomyositis.
The JDM Image Score may have the potential to serve as a reliable biomarker of disease severity and response to therapeutic interventions in children with juvenile dermatomyositis.
Researchers identified independent predictors of short-term dermatomyositis- or polymyositis-related interstitial lung disease mortality.
Tools that can effectively predict course and progression of dermatomyositis can help to identify optimal treatment and ultimately improve quality of life for patients with this rare and debilitating autoimmune disease.
The investigators sought to examine the efficacy and safety of abatacept in patients with DM or PM who were refractory to conventional therapies.
Factors associated with favorable treatment responses to conventional therapy and tacrolimus in myositis-associated interstitial lung disease were examined in a retrospective cohort study.